Literature DB >> 3718838

Unexpected expression of the 250 kD melanoma-associated antigen in human sarcoma cells.

A Godal, O Bruland, E Haug, M Aas, O Fodstad.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3718838      PMCID： PMC2001416          DOI： 10.1038/bjc.1986.142

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  15 in total

1.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

2.  Analysis of hybridoma-exchange antibodies.

Authors:  K O Lloyd; A Albino; A Houghton
Journal:  Hybridoma       Date:  1982

3.  Production and characterization of monoclonal antibody to a melanoma specific glycoprotein.

Authors:  A C Morgan; D R Galloway; R A Reisfeld
Journal:  Hybridoma       Date:  1981

4.  Monoclonal antibody and an antibody-toxin conjugate to a cell surface proteoglycan of melanoma cells suppress in vivo tumor growth.

Authors:  T F Bumol; Q C Wang; R A Reisfeld; N O Kaplan
Journal:  Proc Natl Acad Sci U S A       Date:  1983-01       Impact factor: 11.205

5.  Detection of human osteosarcoma-associated antigen(s) by monoclonal antibodies.

Authors:  S Hosoi; T Nakamura; S Higashi; T Yamamuro; S Toyama; K Shinomiya; H Mikawa
Journal:  Cancer Res       Date:  1982-02       Impact factor: 12.701

6.  Unique glycoprotein-proteoglycan complex defined by monoclonal antibody on human melanoma cells.

Authors:  T F Bumol; R A Reisfeld
Journal:  Proc Natl Acad Sci U S A       Date:  1982-02       Impact factor: 11.205

7.  Radiolocalization of xenografted human malignant melanoma by a monoclonal antibody (9.2.27) to a melanoma-associated antigen in nude mice.

Authors:  K M Hwang; O Fodstad; R K Oldham; A C Morgan
Journal:  Cancer Res       Date:  1985-09       Impact factor: 12.701

8.  Reactivity spectrum of 30 monoclonal antimelanoma antibodies to a panel of 28 melanoma and control cell lines.

Authors:  S Carrel; M Schreyer; A Schmidt-Kessen; J P Mach
Journal:  Hybridoma       Date:  1982

9.  Monoclonal antibodies to 125 kd and 95 kd proteins on human melanoma cells: comparison with other monoclonal-defined melanoma antigens.

Authors:  R E Saxton; B D Mann; D L Morton; M W Burk
Journal:  Hybridoma       Date:  1982

10.  Tissue specificity of anti melanoma monoclonal antibodies analyzed on cell lines.

Authors:  J P Johnson; G Riethmüller
Journal:  Hybridoma       Date:  1982
View more
  8 in total

1.  A monoclonal antibody specific for cells of the melanocyte lineage.

Authors:  C Vennegoor; P Hageman; H Van Nouhuijs; D J Ruiter; J Calafat; P J Ringens; P Rümke
Journal:  Am J Pathol       Date:  1988-01       Impact factor: 4.307

2.  Role of Proteoglycans in Tumor Progression.

Authors:  József Timár; András Jeney; László Kopper
Journal:  Pathol Oncol Res       Date:  1995       Impact factor: 3.201

3.  Osteoblast-induced EGFR/ERBB2 signaling in androgen-sensitive prostate carcinoma cells characterized by multiplex kinase activity profiling.

Authors:  Ase Bratland; Piet J Boender; Hanne K Høifødt; Ingrid H G Østensen; Rob Ruijtenbeek; Meng-Yu Wang; Jens P Berg; Wolfgang Lilleby; Øystein Fodstad; Anne Hansen Ree
Journal:  Clin Exp Metastasis       Date:  2009-03-18       Impact factor: 5.150

4.  Distribution of melanoma specific antibody (HMB-45) in benign and malignant melanocytic tumours. An immunohistochemical study on paraffin sections.

Authors:  R Colombari; F Bonetti; G Zamboni; A Scarpa; F Marino; A Tomezzoli; P Capelli; F Menestrina; M Chilosi; L Fiore-Donati
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1988

5.  RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma.

Authors:  Dennis C Harrer; Bianca Simon; Shin-Ichiro Fujii; Kanako Shimizu; Ugur Uslu; Gerold Schuler; Kerstin F Gerer; Stefanie Hoyer; Jan Dörrie; Niels Schaft
Journal:  BMC Cancer       Date:  2017-08-17       Impact factor: 4.430

6.  Clinical-Scale Production of CAR-T Cells for the Treatment of Melanoma Patients by mRNA Transfection of a CSPG4-Specific CAR under Full GMP Compliance.

Authors:  Manuel Wiesinger; Johannes März; Mirko Kummer; Gerold Schuler; Jan Dörrie; Beatrice Schuler-Thurner; Niels Schaft
Journal:  Cancers (Basel)       Date:  2019-08-16       Impact factor: 6.639

Review 7.  Engineering Approaches in Human Gamma Delta T Cells for Cancer Immunotherapy.

Authors:  Jonathan Fisher; John Anderson
Journal:  Front Immunol       Date:  2018-06-26       Impact factor: 7.561

8.  The Generation of CAR-Transfected Natural Killer T Cells for the Immunotherapy of Melanoma.

Authors:  Bianca Simon; Manuel Wiesinger; Johannes März; Kilian Wistuba-Hamprecht; Benjamin Weide; Beatrice Schuler-Thurner; Gerold Schuler; Jan Dörrie; Ugur Uslu
Journal:  Int J Mol Sci       Date:  2018-08-11       Impact factor: 5.923
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.